TABLE 1—Continued

<table>
<thead>
<tr>
<th>Committee name</th>
<th>Tentative date(s) of meeting(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical Devices Dispute Resolution Panel</td>
<td>Date(s), if needed, to be determined.</td>
</tr>
<tr>
<td>Microbiology Devices Panel</td>
<td>Date(s), if needed, to be determined.</td>
</tr>
<tr>
<td>Molecular and Clinical Genetics Panel</td>
<td>June 27.</td>
</tr>
<tr>
<td>Neurological Devices Panel</td>
<td>Date(s), if needed, to be determined.</td>
</tr>
<tr>
<td>Ophthalmic Devices Panel</td>
<td>November 8–9.</td>
</tr>
<tr>
<td>Orthopedic and Rehabilitation Devices Panel</td>
<td>September 13–14, November 16, December 6–7.</td>
</tr>
<tr>
<td>Radiological Devices Panel</td>
<td>November 2.</td>
</tr>
<tr>
<td>National Mammography Quality Assurance Advisory Committee</td>
<td>October 18.</td>
</tr>
</tbody>
</table>

**CENTER FOR FOOD SAFETY AND APPLIED NUTRITION**

<table>
<thead>
<tr>
<th>Committee name</th>
<th>Tentative date(s) of meeting(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Food Advisory Committee</td>
<td>December 13–14.</td>
</tr>
</tbody>
</table>

**CENTER FOR TOBACCO PRODUCTS**

<table>
<thead>
<tr>
<th>Committee name</th>
<th>Tentative date(s) of meeting(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tobacco Products Scientific Advisory Committee</td>
<td>January 18–20, March 1–2.</td>
</tr>
</tbody>
</table>

**CENTER FOR VETERINARY MEDICINE**

<table>
<thead>
<tr>
<th>Committee name</th>
<th>Tentative date(s) of meeting(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Veterinary Medicine Advisory Committee</td>
<td>Date(s), if needed, to be determined.</td>
</tr>
</tbody>
</table>

**NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH (NCTR)**

<table>
<thead>
<tr>
<th>Committee name</th>
<th>Tentative date(s) of meeting(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Science Advisory Board to NCTR</td>
<td>October 23–24.</td>
</tr>
</tbody>
</table>

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. FDA–2011–N–0002]

**Food and Drug Administration Clinical Trial Requirements, Regulations, Compliance, and Good Clinical Practice; Public Workshop**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of public workshop.

The Food and Drug Administration (FDA), Los Angeles District Office, in cosponsorship with the Society of Clinical Research Associates (SoCRA), is announcing a public workshop. The public workshop on FDA’s clinical trial requirements is designed to aid the clinical research professional’s understanding of the mission, responsibilities, and authority of the FDA and to facilitate interaction with FDA representatives. The program will focus on the relationships among FDA and clinical trial staff, investigators, and institutional review boards (IRB).

Individual FDA representatives will discuss the informed consent process and informed consent documents; regulations relating to drugs, devices, and biologics; as well as inspections of clinical investigators, of IRB, and research sponsors.

**Date and Time:** The public workshop will be held on March 7 and 8, 2012, from 8 a.m. to 5 p.m.

**Location:** The public workshop will be held at the Hyatt Regency Newport Beach, 1107 Jamboree Rd., Newport Beach, CA 92660, 1 (949) 729–1234.

Attendees are responsible for their own accommodations. Please mention SoCRA to receive the hotel room rate of $145.00 plus applicable taxes (available until February 14, 2012, or until the SoCRA room block is filled).

**Contact:** Linda Hartley, Office of Regulatory Affairs, Food and Drug Administration, 19701 Fairchild, Irvine, CA 92612, (949) 608–4413, FAX: (949) 608–4417; or Society of Clinical Research Associates (SoCRA), 530 West Butler Ave., Suite 109, Chalfont, PA 18914, 1 (800) 762–7292 or (215) 822–8644; FAX: (215) 822–8633, email SoCRAmail@aol.com, Web site: www.socra.org.

**Registration:** The registration fee will cover actual expenses including refreshments, lunch, materials, and speaker expenses. Seats are limited; please submit your registration as soon as possible. Workshop space will be filled in order of receipt of registration. Those accepted into the public workshop will receive confirmation.

The cost of the registration is as follows:

**COST OF REGISTRATION**

SoCRA nonmember (includes membership) .............................................. 650.00
Federal Government SoCRA member ......................................................... 450.00
Federal Government SoCRA nonmember ....................................................... 525.00
FDA Employee ....................................................................................... [*]

* Fee Waived.

If you need special accommodations due to a disability, please contact SoCRA or Linda Hartley (see Contact) at least 21 days in advance.

Extended periods of question and answer and discussion have been included in the program schedule. SoCRA designates this education activity for a maximum of 13.3 Continuing Education (CE) Credits for SoCRA CE and continuing nurse education (CNE). SOCRA designates this educational activity for a maximum of 13.3 American Medical Association Physician’s Recognition Award Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation. SoCRA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. SoCRA is an approved provider of CNE by the Pennsylvania State Nurses Association (PSNA), an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel RFA Panel: Challenge on the Transition from Acute to Chronic Neuropathic Pain

Date: January 9–10, 2012.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting)

Contact Person: John Bishop, Ph.D., Scientific Review Officer Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5182, MSC 7844, Bethesda, MD 20892, (301) 405-6964, bishop@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel Member Conflict: Topics in Infectious Diseases and Microbiology

Date: January 12, 2012.

Time: 1 p.m. to 3 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call)

Contact Person: Lianghao Zheng, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3102, MSC 7808, Bethesda, MD 20892, (301) 588-5412, zhengl@csr.nih.gov.


Dated: December 13, 2011.

Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2011–32520 Filed 12–19–11; 8:45 am]

BILLING CODE 4160–01–P

DEPARTMENT OF HOMELAND SECURITY

Office of the Secretary

Published Privacy Impact Assessments on the Web

AGENCY: Privacy Office, DHS.

ACTION: Notice of Publication of Privacy Impact Assessments (PIA).

SUMMARY: The Privacy Office of DHS is making available seven PIAs on various programs and systems in DHS. These assessments were approved and published on the Privacy Office’s web page as of December 20, 2011. The PIAs will be available on the DHS Web site until February 21, 2012, after which they may be obtained by contacting the DHS Privacy Office (contact information below).

FOR FURTHER INFORMATION CONTACT: Mary Ellen Callahan, Chief Privacy Officer, Department of Homeland Security, Washington, DC 20528, or email: pia@hq.dhs.gov.

BILLING CODE 4160–01–P

SUPPLEMENTARY INFORMATION: Between September 1, 2011 and November 30, 2011, the Chief Privacy Officer of the DHS approved and published seven Privacy Impact Assessments (PIAs) on the DHS Privacy Office web site, www.dhs.gov/privacy, under the link for “Privacy Impact Assessments.” These PIAs cover seven separate DHS programs. Below is a short summary of those programs, indicating the DHS component responsible for the system, and the date on which the PIA was approved. Additional information can be found on the web site or by contacting the Privacy Office.

**System: DHS/FEMA/PIA–018 Suspicious Activity Reporting (SAR)**

**Component:** Federal Emergency Management Agency (FEMA).

**Date of approval:** September 9, 2011.

FEMA, a component of DHS, manages a process for SAR. This process, assigned to FEMA’s Office of the Chief Security Officer, is designed to collect, investigate, analyze, and report suspicious activities to the Federal Bureau of Investigation’s (FBI) Joint...